Transgene
Transgene - Model TG4050 -Individualized Therapeutic Vaccine
FromTransgene
A particularly innovative immunotherapy, TG4050 is the lead myvac® candidate. This individualized treatment is based on the specific mutations that are identified in each patient’s tumor.
Most popular related searches
Collaboration agreements
Transgene has signed a strategic collaboration agreement with NEC for the development of TG4050, the first candidate derived from the myvac® platform. This personalized immunotherapy is developed for each patient, on the basis of mutations identified through sequencing of tumor tissue, prioritized using NEC’s Neoantigen Prediction System and delivered using Transgene’s myvac® technological platform which allows development and manufacturing.
